OncoMatch/Clinical Trials/NCT06849986
IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
Is NCT06849986 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Tislelizumab+liposomal doxorubicin+ifosfamide for soft tissue sarcomas.
Treatment: Tislelizumab+liposomal doxorubicin+ifosfamide — This study will enroll patients with specific subtypes of unresectable or metastatic soft tissue sarcoma, and will combine tislelizumab with the standard chemotherapy of liposomal doxorubicin and ifosfamide to initially explore the efficacy and safety.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Sarcoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic therapy for advanced soft tissue sarcoma
Exception: relapsed more than six months after adjuvant therapy with a cumulative dose of doxorubicin ≤300mg/m2
Previous treatment for advanced soft tissue sarcoma, except for those who relapsed more than six months after adjuvant therapy with a cumulative dose of doxorubicin ≤300mg/m2
Cannot have received: experimental or anti-tumor drugs
Received any experimental or anti-tumor drugs within 4 weeks prior to enrollment
Cannot have received: anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody or any other antibodies or drugs specifically targeting T-cell co-stimulation or checkpoint pathways
Previously received any anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody treatment, or any other antibodies or drugs specifically targeting T-cell co-stimulation or checkpoint pathways
Lab requirements
Blood counts
neutrophil count ≥1.5×10⁹/l, platelet count ≥90×10⁹/l, hemoglobin ≥90g/l (no blood transfusion within 14 days)
Kidney function
serum creatinine ≤1.5× uln or creatinine clearance rate ≥50ml/min
Liver function
serum total bilirubin ≤1.5 times uln; alt and ast ≤2.5× uln (≤5× uln for patients with liver metastases)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06849986 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages